Evidence map›Paper›PMID 33363125›Full record

ReviewFrontiers in bioengineering and biotechnology2020

Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies.

Nahla Jemni-Damer, Atocha Guedan-Duran, María Fuentes-Andion, Nora Serrano-Bengoechea, Nuria Alfageme-Lopez, Félix Armada-Maresca, Gustavo V Guinea, José Perez-Rigueiro, Francisco Rojo, Daniel Gonzalez-Nieto and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Outer Retinal Cell Replacement: Putting the Pieces Together.Translational vision science & technology · 2021
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Nahla Jemni-DamerNeuro-computing and Neuro-robotics Research Group, Complutense University of Madrid, Madrid, Spain.
Atocha Guedan-DuranNeuro-computing and Neuro-robotics Research Group, Complutense University of Madrid, Madrid, Spain.
María Fuentes-AndionNeuro-computing and Neuro-robotics Research Group, Complutense University of Madrid, Madrid, Spain.
Nora Serrano-BengoecheaNeuro-computing and Neuro-robotics Research Group, Complutense University of Madrid, Madrid, Spain.
Nuria Alfageme-LopezNeuro-computing and Neuro-robotics Research Group, Complutense University of Madrid, Madrid, Spain.
Félix Armada-MarescaOphthalmology Service, La Paz University Hospital, Madrid, Spain.
Gustavo V GuineaSilk Biomed SL, Madrid, Spain.
José Perez-RigueiroSilk Biomed SL, Madrid, Spain.
Francisco RojoSilk Biomed SL, Madrid, Spain.
Daniel Gonzalez-NietoSilk Biomed SL, Madrid, Spain.
David L KaplanDepartment of Biomedical Engineering, Tufts University, Medford, MA, United States.
Fivos PanetsosNeuro-computing and Neuro-robotics Research Group, Complutense University of Madrid, Madrid, Spain.
Universidad Complutense de Madrid · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESTufts University · USUniversidad Politécnica de Madrid · ESHospital Universitario La Paz · ES

Funding

Translational Bioreactors - Engineering Complex TissuesP41EB002520 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L. · 2004 to 2018
$16.7M
NIBIB NIH HHS P41 EB002520
6 · The paper itself

Abstract

Age-related Macular Degeneration (AMD) is an up-to-date untreatable chronic neurodegenerative eye disease of multifactorial origin, and the main causes of blindness in over 65 y.o. people. It is characterized by a slow progression and the presence of a multitude of factors, highlighting those related to diet, genetic heritage and environmental conditions, present throughout each of the stages of the illness. Current therapeutic approaches, mainly consisting on intraocular drug delivery, are only used for symptoms relief and/or to decelerate the progression of the disease. Furthermore, they are overly simplistic and ignore the complexity of the disease and the enormous differences in the symptomatology between patients. Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, different treatment options have to be considered. Cell therapy is a very promising alternative to drug-based approaches for AMD treatment. Cells delivered to the affected tissue as a suspension have shown poor retention and low survival rate. A solution to these inconveniences has been the encapsulation of these cells on biomaterials, which contrive to their protection, gives them support, and favor their retention of the desired area. We offer a two-papers critical review of the available and under development AMD therapeutic approaches, from a biomaterials and biotechnological point of view. We highlight benefits and limitations and we forecast forthcoming alternatives based on novel biomaterials and biotechnology methods. In this second part we review the preclinical and clinical cell-replacement approaches aiming at the development of efficient AMD-therapies, the employed cell types, as well as the cell-encapsulation and cell-implant systems. We discuss their advantages and disadvantages and how they could improve the survival and integration of the implanted cells.

Indexed as

biomaterialsbiotechnologyBruch’s membranecell replacementcell therapyphotoreceptorsretinal pigment epitheliumtissue engineering

Identifiers

PMID33363125
PMCPMC7758210
OpenAlexW3111314993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.